LB-100   Click here for help

GtoPdb Ligand ID: 11105

Synonyms: LB100
Compound class: Synthetic organic
Comment: LB-100 is a small molecule inhibitor of protein phosphatase 2A (PP2A) [3]. PP2A is a pivotal cellular switch that controls important events that impinge on cellular survival and death, such as cell cycle, apoptosis, and autophagy. PP2A acts on kinase substrates in a number of critical signal transduction pathways (including MAPK, Wnt, PI3K, NF&kappB, PKC, and Ca2+/calmodulin-dependent signalling pathways). PP2A is a validated oncology target. Studies have shown that LB-100 has anti-tumour activity [2] and can sensitise pancreatic cancer to chemotherapy [1] and radiotherapy [3].

LB-100 is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 3
Topological polar surface area 70.08
Molecular weight 268.14
XLogP -1.22
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES CN1CCN(CC1)C(=O)C1[C@@H]2CC[C@H](C1C(=O)O)O2
Isomeric SMILES CN1CCN(CC1)C(=O)C1[C@@H]2CC[C@H](C1C(=O)O)O2
InChI InChI=1S/C13H20N2O4/c1-14-4-6-15(7-5-14)12(16)10-8-2-3-9(19-8)11(10)13(17)18/h8-11H,2-7H2,1H3,(H,17,18)/t8-,9+,10?,11?/m0/s1
InChI Key JUQMLSGOTNKJKI-IZUQBHJASA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
LB-100 has advanced to clinical evaluation in solid tumours and myelodysplastic syndromes.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03027388 Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma Phase 2 Interventional National Institutes of Health Clinical Center (CC)
NCT03886662 A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Phase 1/Phase 2 Interventional Lixte Biotechnology Holdings, Inc.
NCT01837667 Phase I Study of LB-100 With Docetaxel in Solid Tumors Phase 1 Interventional Lixte Biotechnology Holdings, Inc.